Add like
Add dislike
Add to saved papers

Prognostic value of toll-like receptor 4 and nuclear factor-κBp65 in oral squamous cell carcinoma patients.

OBJECTIVE: To investigate toll-like receptor 4 (TLR4) and nuclear factor-κBp65 (NF-κBp65) expression in oral squamous cell carcinoma (OSCC) tissues and the effects of their expression on the outcomes in patients with OSCC.

STUDY DESIGN: TLR4 and NF-κBp65 expression was assessed in 110 patients with OSCC and in 32 normal oral mucosal samples using immunohistochemistry. Correlations between their expression and clinicopathologic parameters, including disease-free survival, disease-specific survival, and overall survival, were analyzed.

RESULTS: High TLR4/NF-κBp65 expression was increased in OSCC tissues compared with normal oral mucosal tissues (all P < .05). High cytoplasmic TLR4 and NF-κBp65 expression was significantly correlated with the primary tumor stage, pN stage, differentiation, invasion depth, and pTNM stage (all P < .05). Cytoplasmic TLR4 expression was associated with NF-κBp65 expression in OSCC (all P < .05). Univariate analysis revealed that high cytoplasmic TLR4 and nuclear NF-κBp65 expression was significantly associated with lower disease-free survival, disease-specific survival, and overall survival rates (all P < .001). Further, multivariate analyses identified high cytoplasmic TLR4 and nuclear NF-κBp65 expression as independent prognostic factors (all P < .05).

CONCLUSIONS: The current findings suggest that the TLR4/NF-κBp65 signaling pathway is associated with survival of patients with OSCC and that it may serve as a potential therapeutic target.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app